| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Oak Ridge Conference |
1 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
2 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA.
3 Tufts University School of Medicine, Howard Hughes Medical Institute, Boston MA.
4 National Ovarian Cancer Early Detection Program, New York University, New York, NY.
5 National Cancer Institute Biomedical Proteomics Program, SAIC, NCI, Frederick, MD.
aAddress correspondence to Dr. Petricoin or Dr. Liotta at: Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110. E-mail lliotta{at}gmu.edu or epetrico{at}gmu.edu.
Abstract
Background: Albumin binds low–molecular-weight molecules, including proteins and peptides, which then acquire its longer half-life, thereby protecting the bound species from kidney clearance. We developed an experimental method to isolate albumin in its native state and to then identify [mass spectrometry (MS) sequencing] the corresponding bound low–molecular-weight molecules. We used this method to analyze pooled sera from a human disease study set (high-risk persons without cancer, n= 40; stage I ovarian cancer, n = 30; stage III ovarian cancer, n = 40) to demonstrate the feasibility of this approach as a discovery method.
Methods: Albumin was isolated by solid-phase affinity capture under native binding and washing conditions. Captured albumin-associated proteins and peptides were separated by gel electrophoresis and subjected to iterative MS sequencing by microcapillary reversed-phase tandem MS. Selected albumin-bound protein fragments were confirmed in human sera by Western blotting and immunocompetition.
Results: In total, 1208 individual protein sequences were predicted from all 3 pools. The predicted sequences were largely fragments derived from proteins with diverse biological functions. More than one third of these fragments were identified by multiple peptide sequences, and more than one half of the identified species were in vivo cleavage products of parent proteins. An estimated 700 serum peptides or proteins were predicted that had not been reported in previous serum databases. Several proteolytic fragments of larger molecules that may be cancer-related were confirmed immunologically in blood by Western blotting and peptide immunocompetition. BRCA2, a 390-kDa low-abundance nuclear protein linked to cancer susceptibility, was represented in sera as a series of specific fragments bound to albumin.
Conclusion: Carrier-protein harvesting provides a rich source of candidate peptides and proteins with potential diverse tissue and cellular origins that may reflect important disease-related information.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  W. G. Miller, D. E. Bruns, G. L. Hortin, S. Sandberg, K. M. Aakre, M. J. McQueen, Y. Itoh, J. C. Lieske, D. W. Seccombe, G. Jones, et al. Current Issues in Measurement and Reporting of Urinary Albumin Excretion Clin. Chem., January 1, 2009; 55(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Norez, M. Pasetto, M. C. Dechecchi, E. Barison, C. Anselmi, A. Tamanini, F. Quiri, L. Cattel, P. Rizzotti, F. Dosio, et al. Chemical conjugation of {Delta}F508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L336 - L347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Oncopeptidomics: A Useful Approach for Cancer Diagnosis? Clin. Chem., June 1, 2007; 53(6): 1004 - 1006. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Lopez, A. Mikulskis, S. Kuzdzal, E. Golenko, E. F. Petricoin III, L. A. Liotta, W. F. Patton, G. R. Whiteley, K. Rosenblatt, P. Gurnani, et al. A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples Clin. Chem., June 1, 2007; 53(6): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mosley, F. W. K. Tam, R. J. Edwards, J. Crozier, C. D. Pusey, and L. Lightstone Urinary proteomic profiles distinguish between active and inactive lupus nephritis Rheumatology, December 1, 2006; 45(12): 1497 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Kazmierczak, A. Gurachevsky, G. Matthes, and V. Muravsky Electron Spin Resonance Spectroscopy of Serum Albumin: A Novel New Test for Cancer Diagnosis and Monitoring Clin. Chem., November 1, 2006; 52(11): 2129 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Hortin The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome Clin. Chem., July 1, 2006; 52(7): 1223 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Hortin, S. A. Jortani, J. C. Ritchie Jr, R. Valdes Jr, and D. W. Chan Proteomics: A New Diagnostic Frontier Clin. Chem., July 1, 2006; 52(7): 1218 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Menard, D. Johann, M. Lowenthal, T. Muanza, M. Sproull, S. Ross, J. Gulley, E. Petricoin, C. N. Coleman, G. Whiteley, et al. Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis Cancer Res., February 1, 2006; 66(3): 1844 - 1850. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
